These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 364571)

  • 1. Elimination and organ distribution of intravenously administered allogeneic and xenogeneic IgG modifications. (Standard IgG, F (ab)2-fragments and beta-propiolactone treated IgG) in dogs.
    Ring J; Duswald KH; Bachmann T; von Scheel J; Stephan W; Brendel W
    Res Exp Med (Berl); 1978 Sep; 173(3):209-18. PubMed ID: 364571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Concentration of intravenously administered gammaglobulin preparations in dog skin (author's transl)].
    Ring J; Duswald KH; Bachmann T; Stephan W; Brendel W
    Arch Dermatol Res (1975); 1977 Dec; 260(3):201-6. PubMed ID: 74982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced pepsin digestion: a novel process for purifying antibody F(ab')(2) fragments in high yield from serum.
    Jones RG; Landon J
    J Immunol Methods; 2002 May; 263(1-2):57-74. PubMed ID: 12009204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of whole serum and prepurified IgG digestion by pepsin for F(ab')2 manufacture.
    Boushaba R; Kumpalume P; Slater NK
    Biotechnol Prog; 2003; 19(4):1176-82. PubMed ID: 12892479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composition of immune deposits present in glomeruli of NZB/W F1 mice.
    Sugisaki T; Takase S
    Clin Immunol Immunopathol; 1991 Dec; 61(3):296-308. PubMed ID: 1934620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.
    Smith TW; Lloyd BL; Spicer N; Haber E
    Clin Exp Immunol; 1979 Jun; 36(3):384-96. PubMed ID: 114346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Various immunoglobulin preparations for intravenous use.
    Morell A
    Vox Sang; 1986; 51 Suppl 2():44-9. PubMed ID: 2945321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin.
    Ismail M; Abd-Elsalam MA; Al-Ahaidib MS
    Toxicon; 1998 Jan; 36(1):93-114. PubMed ID: 9604285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies.
    Holton OD; Black CD; Parker RJ; Covell DG; Barbet J; Sieber SM; Talley MJ; Weinstein JN
    J Immunol; 1987 Nov; 139(9):3041-9. PubMed ID: 3499463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application--a case report.
    Höckel M; Kaufmann R
    J Perinat Med; 1986; 14(3):205-8. PubMed ID: 3783391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Human i.v. immune globulin by chemical modification with beta-propiolactone/radiochemical study (author's transl)].
    Stephan W; Fasold H
    Arzneimittelforschung; 1980; 30(12):2090-3. PubMed ID: 7194066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of beta-propiolactone treatment on the complement activation mediated by equine antisera.
    Guidolin R; Morais JF; Stephano MA; Marcelino JR; Yamaguchi IK; Higashi HG
    Rev Inst Med Trop Sao Paulo; 1997; 39(2):119-22. PubMed ID: 9394526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences among available immunoglobulin preparations for intravenous use.
    Skvaril F; Gardi A
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S43-8. PubMed ID: 2456510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streptococcal protein G has affinity for both Fab- and Fc-fragments of human IgG.
    Erntell M; Myhre EB; Sjöbring U; Björck L
    Mol Immunol; 1988 Feb; 25(2):121-6. PubMed ID: 3131664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and characterization of anti-human IgG F(ab')2 antibody fragment.
    Valedkarimi Z; Nasiri H; Aghebati-Maleki L; Abdolalizadeh J; Esparvarinha M; Majidi J
    Hum Antibodies; 2018; 26(4):171-176. PubMed ID: 29689714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-step purification of pepsin-derived monoclonal antibody fragments from crude murine ascitic fluids by ceramic hydroxyapatite high-performance liquid chromatography.
    Moro A; Yoshitake T; Ogawa T; Ichimura T
    J Biochem; 2008 Dec; 144(6):733-9. PubMed ID: 18835826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved method for pepsinolysis of mouse IgG(1) molecules to F(ab')(2) fragments.
    Wilson DS; Wu J; Peluso P; Nock S
    J Immunol Methods; 2002 Feb; 260(1-2):29-36. PubMed ID: 11792373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat.
    Bazin-Redureau MI; Renard CB; Scherrmann JM
    J Pharm Pharmacol; 1997 Mar; 49(3):277-81. PubMed ID: 9231345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mutagenicity and immunogenicity of a beta-propiolactone-treated therapeutic IgG-preparation.
    Pincus JH; Mortelmans K; Tanaka W; Stephan W; Lissner R
    Arzneimittelforschung; 1981; 31(11):1924-8. PubMed ID: 6172136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low temperature pepsin proteolysis. An effective procedure for mouse IgM F(ab')2 fragment production.
    Pascual DW; Clem LW
    J Immunol Methods; 1992 Feb; 146(2):249-55. PubMed ID: 1538146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.